Abstract
As predicted by fuzzy-trace theory, people with a range of training—from untrained adolescents to expert physicians—are susceptible to biases and errors in judgment and perception of HIV-AIDS risk. To explain why this occurs, we introduce fuzzy-trace theory as a theoretical perspective that describes these errors to be a function of knowledge deficits, gist-based representation of risk categories, retrieval failure for risk knowledge, and processing interference (e.g., base-rate neglect) in combining risk estimates. These principles explain how people perceive HIV-AIDS risk and why they take risks with potentially lethal outcomes, often despite rote (verbatim) knowledge.For example, people inappropriately generalize the wrong gist about condoms’ effectiveness against fluid-borne disease to diseases that are transferred skin-to-skin, such as HPV. We also describe how variation in processing in adolescence (e.g., more verbatim processing compared to adults) can be a route to risk-taking that explains key aspects of why many people are infected with HIV in youth, as well as how interventions that emphasize bottom-line gists communicate risks effectively.
Keywords: Class inclusion, development, fuzzy-trace theory, health, judgment, risk communication.
Current HIV Research
Title:Gist Representations and Communication of Risks about HIV-AIDS: A Fuzzy-Trace Theory Approach
Volume: 13 Issue: 5
Author(s): Evan A. Wilhelms, Valerie F. Reyna, Priscila Brust-Renck, Rebecca B. Weldon and Jonathan C. Corbin
Affiliation:
Keywords: Class inclusion, development, fuzzy-trace theory, health, judgment, risk communication.
Abstract: As predicted by fuzzy-trace theory, people with a range of training—from untrained adolescents to expert physicians—are susceptible to biases and errors in judgment and perception of HIV-AIDS risk. To explain why this occurs, we introduce fuzzy-trace theory as a theoretical perspective that describes these errors to be a function of knowledge deficits, gist-based representation of risk categories, retrieval failure for risk knowledge, and processing interference (e.g., base-rate neglect) in combining risk estimates. These principles explain how people perceive HIV-AIDS risk and why they take risks with potentially lethal outcomes, often despite rote (verbatim) knowledge.For example, people inappropriately generalize the wrong gist about condoms’ effectiveness against fluid-borne disease to diseases that are transferred skin-to-skin, such as HPV. We also describe how variation in processing in adolescence (e.g., more verbatim processing compared to adults) can be a route to risk-taking that explains key aspects of why many people are infected with HIV in youth, as well as how interventions that emphasize bottom-line gists communicate risks effectively.
Export Options
About this article
Cite this article as:
Wilhelms A. Evan, Reyna F. Valerie, Brust-Renck Priscila, Weldon B. Rebecca and Corbin C. Jonathan, Gist Representations and Communication of Risks about HIV-AIDS: A Fuzzy-Trace Theory Approach, Current HIV Research 2015; 13 (5) . https://dx.doi.org/10.2174/1570162X13666150511142748
DOI https://dx.doi.org/10.2174/1570162X13666150511142748 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Synthesis, Biological Investigation and Docking Study of Novel Chromen Derivatives as Anti-Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry Novel Approaches for Allergy
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents The Discovery of the Potent and Selective Antitumour Agent 2-(4-Amino-3-methylphenyl)benzothiazole (DF 203) and Related Compounds
Current Medicinal Chemistry Beta-cell Management in Type 2 Diabetes: Beneficial Role of Nutraceuticals
Endocrine, Metabolic & Immune Disorders - Drug Targets Gallic Acid and Gallic Acid Derivatives: Effects on Drug Metabolizing Enzymes
Current Drug Metabolism Artemisinin, Promising Lead Natural Product for Various Drug Developments
Mini-Reviews in Medicinal Chemistry Decision Support System for Lymphoma Classification
Current Medical Imaging Molecular Biotheranostic Approaches of Cancers Using LAT Kit Probes
Current Medical Imaging Ribosome-inactivating Proteins from Root Tubers and Seeds of Trichosan-thes kirilowii and Other Trichosanthes Species
Protein & Peptide Letters An Overview of Piperazine Scaffold as Promising Nucleus for Different Therapeutic Targets
Current Pharmaceutical Design A Review of Pharmacological Treatment Options for Lung Cancer: Emphasis on Novel Nanotherapeutics and Associated Toxicity
Current Drug Targets Aneuploidy-Inducing Mutations in Mitotic Checkpoint Protein hMad1-Carboxi Terminal Domain Analyzed by SAR and Computational Mutagenesis
Current Proteomics The Quinoline Imidoselenocarbamate EI201 Blocks the AKT/mTOR Pathway and Targets Cancer Stem Cells Leading to a Strong Antitumor Activity
Current Medicinal Chemistry A Review of the ADAMTS Family, Pharmaceutical Targets of the Future
Current Pharmaceutical Design CXCR3-binding Chemokines: Novel Multifunctional Therapeutic Targets
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Therapeutic Strategies to Target Multiple Kinases in Glioblastoma
Anti-Cancer Agents in Medicinal Chemistry Pharmacogenomic Approaches to Osteoporosis: 2005 Update
Current Pharmacogenomics TNF α Signaling Beholds Thalidomide Saga: A Review of Mechanistic Role of TNF-α Signaling Under Thalidomide
Current Topics in Medicinal Chemistry Molecular Interaction and Computational Analytical Studies of Pinocembrin for its Antiangiogenic Potential Targeting VEGFR-2: A Persuader of Metastasis
Medicinal Chemistry TGF-beta Signaling in Cancer Treatment
Current Pharmaceutical Design